> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Guide on Bladder Cancer Drug Development
- URL: https://www.fdaweb.com/guide-on-bladder-cancer-drug-development-2/
- Published: 2022-06-28T12:00:00.000Z
- Updated: 2026-09-14T17:50:28.000Z
- Author: David McFarland
- Tags: FDA Policy/General, #legacy-id-D5152183

*Federal Register* notice: FDA has made available a final guidance entitled “Bladder Cancer: Developing Drugs and Biologics for Adjuvant Treatment.” The document is intended to aid sponsors developing drugs and biologics for the adjuvant treatment of muscle-invasive bladder cancer. It provides recommendations on eligibility criteria, choice of comparator, follow-up imaging assessments, determination of disease recurrence, analyses of disease-free survival, and interpretation of trial results. To view the notice, click [here](https://www.govinfo.gov/content/pkg/FR-2022-06-28/pdf/2022-13753.pdf?ref=fdaweb.com).